Topical Clindamycin: A Safe Choice for Acne Treatment Despite GI Concerns
A recent review highlighted the safety of topical clindamycin, a popular antibiotic treatment for acne vulgaris.
Related Articles
Apremilast for Pediatric Patients With Moderate To Severe Plaque Psoriasis
Researchers aimed to evaluate the efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis.
Jessner Lymphocytic Infiltrate in Anti-HMGCR Myopathy
This case report describes a man in his 50s with type 2 diabetes and hyperlipidemia who was admitted for rash and proximal muscle weakness, pain,…
Making Strides for Skin Health Equity in 2024: Reviewing a Year of Progress
Dermatology Times is looking back on the top stories in dermatology that involve strides in skin health equity: addressing disparities for skin of color, women,…
Dispelling Skin Myths: A New Era of Preventative Care for Anti-Aging, Cleansing, and Sunscreen
Renata Block, MMS, PA-C; Ted Lain, MD, MBA, FAAD; Zoe Diana Draelos, MD; and Cheri Frey, MD, FAAD, bust common skin care myths in a…
Issue – JDDonline – Journal of Drugs in Dermatology
Copy: Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age. As almost half of pregnancies in the United States are unplanned, dermatologists must give special…
Long-Term Risk of Autoimmune and Autoinflammatory Disorders After COVID-19
This cohort study investigates the long-term risk of autoimmune and autoinflammatory diseases among patients in South Korea who had a COVID-19 diagnosis using an extended…
Immune Checkpoint Inhibitor–Induced Vitiligo-Like Depigmentation
This retrospective case series compares vitiligo resulting from immune checkpoint inhibitor (ICI) therapy vs preexisting vitiligo among patients receiving ICI treatment for cancer.
Primary Biliary Cirrhosis and Psoriasis Co-Occurrence
Researchers investigated the potential causal relationship between primary biliary cirrhosis and psoriasis.
Bullous Arthropod Reaction Secondary to Ctenocephalides felis
This case report describes a woman in her 40s who presented for evaluation of pruritic skin lesions on her chest and all 4 extremities that…
Phase 3 Trials Confirm Deucravacitinib’s Efficacy in PsA
Deucravacitinib achieved ACR20 response in PsA patients at Week 16, with a safety profile consistent with previous studies.